Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-619,249
Closed -$17.4M 8606
2016
Q4
$17.4M Buy
619,249
+611,806
+8,220% +$17.1M 0.02% 961
2016
Q3
$204K Sell
7,443
-1,283,010
-99% -$35.2M ﹤0.01% 6288
2016
Q2
$28.1M Buy
+1,290,453
New +$28.1M 0.03% 583
2015
Q4
Sell
-226,458
Closed -$5.84M 9843
2015
Q3
$5.84M Buy
226,458
+217,706
+2,488% +$5.62M 0.01% 1792
2015
Q2
$217K Buy
+8,752
New +$217K ﹤0.01% 6216
2014
Q3
Sell
-822
Closed -$20K 8879
2014
Q2
$20K Sell
822
-729,865
-100% -$17.8M ﹤0.01% 7304
2014
Q1
$15.4M Buy
730,687
+207,994
+40% +$4.39M 0.02% 995
2013
Q4
$12.4M Buy
+522,693
New +$12.4M 0.02% 1075

Other funds holding QGENF

Ken Griffin's QGENF Position: Q1 2017 in Review

Ken Griffin sold out of QIAGEN NV (QGENF) in Q1 2017, closing a stake of 619,249 shares — an estimated $17.4M sold.

Ken Griffin first reported a position in QGENF in Q4 2013 and held it in 8 quarters. The position peaked at $28.1M in Q2 2016. 6 funds tracked by Wall St. Rank hold QGENF as of Q1 2017.

  • Ken Griffin reported no remaining QIAGEN NV position as of Q1 2017 after selling out during the quarter.
  • Ken Griffin sold 619,249 QIAGEN NV shares in Q1 2017, an estimated $17.4M.
  • Ken Griffin first reported a position in QIAGEN NV in Q4 2013 and held it in 8 quarters.
  • Ken Griffin's QIAGEN NV position peaked at $28.1M in Q2 2016.
  • 6 funds tracked by Wall St. Rank held QIAGEN NV as of Q1 2017.

Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.